Myricx Bio announced that it has received £90 million in a round of funding co-led by new investors Novo Holdings A/S and Abingworth LLP on July 8, 2024. The transaction included participation from new investors Cancer Research Horizons, Cancer Research Horizons, Eli Lilly and Company, returning investors Brandon Capital Partners and Sofinnova Partners SAS. Michael Bauer from Novo Holdings A/S and Lucille Conroy from Abingworth LLP will join board of directors.